WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Commitment to Sustainability

• The company is committed to social responsibility and works with customers around the world to create long-term value for all stakeholders.
• The company has made significant progress on climate change, reducing its Scope 1 and 2 greenhouse gas emissions intensity by 29% compared to the base year of 2020.
• The company is ahead of schedule to reduce water intensity by 18% by 2025 and further upgraded to 30%.
• The company employs more than 12,000 people from 56 countries, with 53% of employees in science, technology, engineering and mathematics (STEM) roles.
• The company has been widely recognized by mainstream ESG rating agencies, maintaining its leading position in the industry's ESG leadership.

HONG KONG, April 30, 2024 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global contract research, development and manufacturing CRDMO company, today released its 2023 Environmental, Social and Governance (ESG) Report, showcasing the company's tangible progress in sustainability over the past year.

WuXi Biologics' ESG strategy has always been guided by the company's vision and mission, and is fully integrated into the company's global business operations. In 2023, WuXi Biologics joined the United Nations Global Compact to fulfill its commitment to corporate and social sustainability. In addition, WuXi Biologics has been recognized by major ESG rating agencies for its outstanding progress in the field of ESG, including being included in the S&P Dow Jones Sustainability World Index and Emerging Markets Index, receiving a AAA rating in MSCI's ESG Ratings, receiving a "Platinum" medal from EcoVadis, and being awarded the "Highest Rated in Industry" and "Highest Rated in the Region" by Morningstar Sustainalytics for four consecutive years. Ranked on CDP's Water Security 'A' List and achieved an A- in the CDP Climate Change Leadership Rating.

Chief Executive Officer, WuXi Biologics, ESG Chairman of the Committee, Dr. Chan Chi-seng

"As a member of the United Nations Global Compact, the world's largest international organization promoting corporate social responsibility and sustainability, WuXi Biologics has always regarded sustainability as a cornerstone of its business development strategy. In 2023, WuXi Biologics leveraged its unique CRDMO business model to achieve steady growth. The company abides by its commitments, bravely assumes social responsibility, and works with global customers to continuously create positive environmental and social benefits in all aspects of the industrial value chain. "

WuXi Biologics' 2023 ESG Report provides a comprehensive and transparent overview of the company's ESG strategy and its outstanding progress on material issues such as employees, global partners, communities, and the environment.

Strengthen corporate governance

Guided by its ESG strategy, WuXi Biologics has established a comprehensive ESG governance structure, including an ESG committee composed of board members to perform regulatory duties, an ESG steering group to provide key insights, a dedicated ESG department to effectively drive strategy execution, and a dedicated working group on key issues. The company adheres to the highest standards of integrity and business ethics and has a zero-tolerance policy for business ethics issues. In 2023, the Company established the Ethics and Compliance Committee as the highest management body of the compliance system to further enhance its ability to prevent and respond to compliance risks. In addition, the company actively embraces the United Nations Sustainable Development Goals, formulates a scientific, reasonable and quantifiable ESG target matrix and roadmap, continuously tracks progress, and continuously optimizes.

Actively respond to climate change

The pursuit of environmental sustainability has become the only way for responsible corporate citizens to achieve long-term sustainable development. In 2023, WuXi Biologics signed the Science Based Targets initiative (SBTi) pledge to embark on a new journey toward net-zero emissions. The company actively reduces carbon emissions and tackles climate change through a series of substantive initiatives. Reduce Scope 1 and 2 GHG emissions intensity by 29% in 2023 compared to the base year of 2020. In addition, the company has achieved excellence in the field of water management. In 2023, the company achieved its water conservation target of reducing water intensity by 18% by 2025 from 2019 as the base year, and further upgraded this target to 30%.

Build a sustainable value chain

Committed to openness and transparency, WuXi Biologics is committed to working closely with all stakeholders. WuXi Biologics selects its supply chain business partners in accordance with WuXi Biologics' Code of Ethical Conduct, and incorporates environmental and social sustainability performance into its supplier evaluation system. WuXi Biologics works closely with its supply chain business partners to create a positive impact across the value chain through rigorous access screening, regular assessments and audits, and ongoing training to share best practices.

Championing a culture of diversity, equity, and inclusion

Talent is a key strength in WuXi Biologics' business development. The company currently has more than 12,000 professionally skilled and dedicated employees from 56 countries and regions with diverse cultural backgrounds. In order to continue to promote inclusion, equality and diversity (DEI), the company has established a DEI committee composed of employee representatives from different departments and backgrounds to formulate and monitor DEI strategies and implementation. The company encourages women to pursue careers in STEM (science, technology, engineering and mathematics) fields. In 2023, WuXi Biologics will account for 53% of women in STEM jobs, far exceeding the industry average.

Practice corporate social responsibility

Community giving back is a vital part of WuXi Biologics' corporate social responsibility. In 2023, the company's employees will accumulate more than 8,000 volunteer hours. Unleashing our technological strengths to empower our global customers and patients is one of WuXi Biologics' three pillars of corporate social responsibility. WuXi Biologics is actively empowering customers around the world to develop rare disease drugs, and currently has a total of 19 rare disease programs on the company's integrated platform. In 2023, WuXi Biologics successfully approved an innovative treatment for Pompe disease in the European Union, the United Kingdom, and the United States. To celebrate this milestone, WuXi Biologics launched the "Run for Health" charity run to support rare disease students, with more than 1,500 employee volunteers from 10 sites around the world participating.

CRDMO Green and low-carbon solutions

To continue to drive technological innovation and accelerate the environmental and low-carbon transformation of the global biologics industry, WuXi Biologics has integrated ESG concepts into multiple in-house innovation platforms, including WuXiBody™, WuXiUP™, and WuXiUI™, to provide global customers with end-to-end green and low-carbon CRDMO solutions throughout drug discovery, development, and manufacturing. At the same time, with the help of lean management and improvement tools, the company completed more than 150 ESG lean improvement projects in 2023, improving operational efficiency, reducing resource consumption, and achieving both environmental and economic benefits.

Dr. Chen Zhisheng

"We are very proud of the many fruitful progress we have made towards our ESG goals. More importantly, the outstanding results we strive to achieve can create well-being for more people. Looking forward to 2024, we will maintain our faith, move forward bravely, always integrate the concept of sustainable development into business development, and continue to empower global customers to develop innovative drugs, benefit patients, and contribute to the cause of human health. "

To view the full 2023 ESG Report, please visit:

About WuXi Biologics

WuXi Biologics (Stock Code: 2269.HK) HK) is a leading global contract research, development and manufacturing (CRDMO) company. Through an open, integrated biopharmaceutical capability and technology enablement platform, the company provides a full range of end-to-end services to help partners discover, develop and manufacture biologics, realize the whole process from concept to commercial manufacturing, accelerate the global biopharmaceutical R&D process, reduce R&D costs, and benefit patients.

WuXi Biologics has more than 12,000 employees in China, the U.S., Ireland, Germany and Singapore. Through WuXi Biologics' dedicated service team, advanced technology and insights, the company provides customers with efficient and cost-effective biologics solutions. As of the end of December 2023, WuXi Biologics had 698 integrated projects for R&D and manufacturing, including 24 commercial manufacturing projects.

WuXi Biologics considers Environmental, Social and Governance (ESG) to be an important part of its business development and corporate spirit, and is committed to becoming an ESG leader in the global biologics CRDMO field, such as leading the industry in the application of greener next-generation biologics technologies and energy. The company has established an ESG Committee led by the CEO to fully implement the ESG strategy and fulfill its commitment to sustainable development. For more information, please visit: